Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon/Chiron Myotrophin review goal date is Nov. 11 after submission of NDA amendment.

Executive Summary

CEPHALON MYOTROPHIN REVIEW GOAL DATE SET FOR NOV. 11 following submission of an amendment by Chiron and Cephalon several weeks before the Aug. 11 priority review deadline for insulin-like growth factor for treatment of amyotrophic lateral sclerosis. The companies submitted the NDA for Myotrophin (mecasermin) on Feb. 11. The drug was not recommended for approval by the Peripheral & Central Nervous System Drugs Advisory Committee on May 8 ("The Pink Sheet" May 12, p. 7). The extension in the review deadline will buy some time for FDA. The agency has indicated that it believes another study is necessary to support approval; a rejection letter, however, would trigger a wave of unwelcome publicity for the agency with media coverage in the past month heavily focused on patients advocating approval of the agent.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS030675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel